FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1913626564> ?p ?o ?g. }

• W1913626564 endingPage "545" @default.
• W1913626564 startingPage "S" @default.
• W1913626564 abstract "Introduction: In patients with chronic constipation (CC), treatment with the selective, highaffinity 5-HT4 receptor agonist prucalopride is associated with improvements in colonic transit time (CTT) that correlate with bowel movement frequency. The aim of this analysis was to assess the relationship between CTT and gastrointestinal symptoms in relation to prucalopride use. Methods: An integrated analysis was conducted of three randomized, placebo-controlled, phase 2 dose-finding trials of prucalopride in patients with CC. CC was defined as ≤3 spontaneous complete bowel movements per week as well as straining, sensation of incomplete evacuation, or hard stools for ≥25% of stools. Patients with secondary constipation were excluded. CTT was assessed at pre-selected study sites at the start and end of treatment, using radio-opaque markers, when the patients were not taking laxatives. Slow CTT was defined as ≥48 hours and very slow CTT as ≥96 hours. At every visit, patients assessed the presence and severity of their symptoms (absent, very mild, mild, moderate, marked, severe and very severe). Results: Overall, 280 patients had CTT assessments at both baseline and final visit and were included in this analysis. Of these, 112 were treated with placebo, 98 with prucalopride 2mg and 70 with prucalopride 4mg. Average patient age was 43 years; average duration of constipation was 19 years; and 93% of patients were female. Overall, mean baseline CTT was 66 hours (range: 2-144 hours) and 70% of patients (n = 196) had slow CTT. After treatment with prucalopride 2mg and 4mg, CTT was reduced by 12 hours (95% confidence interval [CI]: -18.9, -5.1) and 14 hours (CI: -20.5, -7.4), respectively; CTT increased by 0.5 hours (CI: -4.5, +5.5) with placebo. Of patients with slow CTT at baseline, 16%, 68% and 65% had normal CTT after treatment with placebo, prucalopride 2mg and prucalopride 4mg, respectively. A higher proportion of patients with slow or very slow CTT at the end of the study had severe/very severe abdominal pain/cramps, straining symptoms or unproductive calls to defecate, compared with patients with normal CTT (Figure 1). Severe/very severe urgency was less common in the slow and very slow CTT groups than in patients with normal CTT. For other symptoms such as fatigue, abdominal bloating, flatulence and distension, a relationship with CTT was less clear. Conclusions: This study is the first to show a relationship between idiopathic slow CTT and symptom severity in patients with CC. Slower CTT is associated with a greater need to strain, unproductive calls to defecate and abdominal pain/cramps. Figure 1. Relationship between transit time at the end of treatment and the proportion of patients with severe or very severe symptoms for (A) abdominal pain/cramps and straining and (B) unproductive calls to defecate and urgency. CTT, colonic transit time." @default.
• W1913626564 created "2016-06-24" @default.
• W1913626564 creator A5003911184 @default.
• W1913626564 creator A5070556531 @default.
• W1913626564 creator A5085844739 @default.
• W1913626564 creator A5091176390 @default.
• W1913626564 date "2013-05-01" @default.
• W1913626564 modified "2023-10-18" @default.
• W1913626564 title "Su2061 Relationship Between Colonic Transit Time and Symptoms of Constipation: Integrated Results From Clinical Trials of Prucalopride" @default.
• W1913626564 doi "https://doi.org/10.1016/s0016-5085(13)62023-5" @default.
• W1913626564 hasPublicationYear "2013" @default.
• W1913626564 type Work @default.
• W1913626564 sameAs 1913626564 @default.
• W1913626564 citedByCount "2" @default.
• W1913626564 countsByYear W19136265642013 @default.
• W1913626564 crossrefType "journal-article" @default.
• W1913626564 hasAuthorship W1913626564A5003911184 @default.
• W1913626564 hasAuthorship W1913626564A5070556531 @default.
• W1913626564 hasAuthorship W1913626564A5085844739 @default.
• W1913626564 hasAuthorship W1913626564A5091176390 @default.
• W1913626564 hasBestOaLocation W19136265641 @default.
• W1913626564 hasConcept C126322002 @default.
• W1913626564 hasConcept C127413603 @default.
• W1913626564 hasConcept C22212356 @default.
• W1913626564 hasConcept C2781112942 @default.
• W1913626564 hasConcept C2911073721 @default.
• W1913626564 hasConcept C3018129524 @default.
• W1913626564 hasConcept C535046627 @default.
• W1913626564 hasConcept C71924100 @default.
• W1913626564 hasConcept C90924648 @default.
• W1913626564 hasConceptScore W1913626564C126322002 @default.
• W1913626564 hasConceptScore W1913626564C127413603 @default.
• W1913626564 hasConceptScore W1913626564C22212356 @default.
• W1913626564 hasConceptScore W1913626564C2781112942 @default.
• W1913626564 hasConceptScore W1913626564C2911073721 @default.
• W1913626564 hasConceptScore W1913626564C3018129524 @default.
• W1913626564 hasConceptScore W1913626564C535046627 @default.
• W1913626564 hasConceptScore W1913626564C71924100 @default.
• W1913626564 hasConceptScore W1913626564C90924648 @default.
• W1913626564 hasIssue "5" @default.
• W1913626564 hasLocation W19136265641 @default.
• W1913626564 hasOpenAccess W1913626564 @default.
• W1913626564 hasPrimaryLocation W19136265641 @default.
• W1913626564 hasRelatedWork W1635029339 @default.
• W1913626564 hasRelatedWork W1965029547 @default.
• W1913626564 hasRelatedWork W2021245872 @default.
• W1913626564 hasRelatedWork W2040974724 @default.
• W1913626564 hasRelatedWork W2086375515 @default.
• W1913626564 hasRelatedWork W2086526221 @default.
• W1913626564 hasRelatedWork W2091560900 @default.
• W1913626564 hasRelatedWork W2321210699 @default.
• W1913626564 hasRelatedWork W2519485870 @default.
• W1913626564 hasRelatedWork W2897317802 @default.
• W1913626564 hasVolume "144" @default.
• W1913626564 isParatext "false" @default.
• W1913626564 isRetracted "false" @default.
• W1913626564 magId "1913626564" @default.
• W1913626564 workType "article" @default.